275 related articles for article (PubMed ID: 30760286)
21. Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.
Banerjee S; Oza AM; Birrer MJ; Hamilton EP; Hasan J; Leary A; Moore KN; Mackowiak-Matejczyk B; Pikiel J; Ray-Coquard I; Trask P; Lin K; Schuth E; Vaze A; Choi Y; Marsters JC; Maslyar DJ; Lemahieu V; Wang Y; Humke EW; Liu JF
Ann Oncol; 2018 Apr; 29(4):917-923. PubMed ID: 29401246
[TBL] [Abstract][Full Text] [Related]
22. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.
Ferrandina G; Ludovisi M; Lorusso D; Pignata S; Breda E; Savarese A; Del Medico P; Scaltriti L; Katsaros D; Priolo D; Scambia G
J Clin Oncol; 2008 Feb; 26(6):890-6. PubMed ID: 18281662
[TBL] [Abstract][Full Text] [Related]
23. [Safety of PLD in the treatment of the patients with recurrent ovarian cancer--clinical experience].
Malkowska-Walczak B; Nowak-Markwitz E; Spaczyński M
Ginekol Pol; 2009 Sep; 80(9):682-6. PubMed ID: 19886242
[TBL] [Abstract][Full Text] [Related]
24. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G;
Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414
[TBL] [Abstract][Full Text] [Related]
25. Adverse Event Profile by Folate Receptor Status for Vintafolide and Pegylated Liposomal Doxorubicin in Combination, Versus Pegylated Liposomal Doxorubicin Alone, in Platinum-Resistant Ovarian Cancer: Exploratory Analysis of the Phase II PRECEDENT Trial.
Herzog TJ; Kutarska E; Bidzińsk M; Symanowski J; Nguyen B; Rangwala RA; Naumann RW
Int J Gynecol Cancer; 2016 Nov; 26(9):1580-1585. PubMed ID: 27654255
[TBL] [Abstract][Full Text] [Related]
26. Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer.
Fuh KC; Bookman MA; Liu JF; Coleman RL; Herzog TJ; Thaker PH; Monk BJ; Anderson R; McIntyre G; Rangwala R; Moore KN
Gynecol Oncol; 2021 Nov; 163(2):254-261. PubMed ID: 34474927
[TBL] [Abstract][Full Text] [Related]
27. An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.
Parma G; Mancari R; Del Conte G; Scambia G; Gadducci A; Hess D; Katsaros D; Sessa C; Rinaldi A; Bertoni F; Vitali A; Catapano CV; Marsoni S; van de Velde H; Colombo N
Int J Gynecol Cancer; 2012 Jun; 22(5):792-800. PubMed ID: 22635029
[TBL] [Abstract][Full Text] [Related]
28. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J;
Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074
[TBL] [Abstract][Full Text] [Related]
29. The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials.
Gibson JM; Alzghari S; Ahn C; Trantham H; La-Beck NM
Oncologist; 2013; 18(9):1022-31. PubMed ID: 23881990
[TBL] [Abstract][Full Text] [Related]
30. Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients.
Ko EM; Lippmann Q; Caron WP; Zamboni W; Gehrig PA
Gynecol Oncol; 2013 Dec; 131(3):683-8. PubMed ID: 24096112
[TBL] [Abstract][Full Text] [Related]
31. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T
Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190
[TBL] [Abstract][Full Text] [Related]
32. Trabectedin + pegylated liposomal doxorubicin in third-line treatment of platinum-sensitive relapsed ovarian cancer: a case study.
Marth C
Expert Rev Anticancer Ther; 2018 Oct; 18(sup1):19-22. PubMed ID: 30223697
[TBL] [Abstract][Full Text] [Related]
33. Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations.
Hollis RL; Meynert AM; Churchman M; Rye T; Mackean M; Nussey F; Arends MJ; Sims AH; Semple CA; Herrington CS; Gourley C
BMC Cancer; 2018 Jan; 18(1):16. PubMed ID: 29298688
[TBL] [Abstract][Full Text] [Related]
34. Extracorporeal Elimination of Circulating Pegylated Liposomal Doxorubicin (PLD) to Enhance the Benefit of Cytostatic Therapy in Platinum-Resistant Ovarian Cancer Patients.
Kubeček O; Bláha M; Diaz-Garcia D; Filip S
Acta Medica (Hradec Kralove); 2015; 58(1):3-8. PubMed ID: 26454800
[TBL] [Abstract][Full Text] [Related]
35. A comparison of overall survival with 40 and 50mg/m
Nakayama M; Kobayashi H; Takahara T; Nishimura Y; Fukushima K; Yoshizawa K
Gynecol Oncol; 2016 Nov; 143(2):246-251. PubMed ID: 27612976
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
Strauss HG; Hemsen A; Karbe I; Lautenschläger C; Persing M; Thomssen C
Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221
[TBL] [Abstract][Full Text] [Related]
37. Recurrent ovarian cancer: treatment with pegylated liposomal doxorubicin; a Westmead Cancer Care Centre experience.
Dear RF; Gao B; Harnett P
Asia Pac J Clin Oncol; 2010 Mar; 6(1):66-73. PubMed ID: 20398040
[TBL] [Abstract][Full Text] [Related]
38. A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.
Vergote I; Schilder RJ; Pippitt CH; Wong S; Gordon AN; Scudder S; Kridelka F; Dirix L; Leach JW; Ananda S; Nanayakkara N; Melara R; Bass MB; Litten J; Adewoye H; Wenham RM
Gynecol Oncol; 2014 Oct; 135(1):25-33. PubMed ID: 25019569
[TBL] [Abstract][Full Text] [Related]
39. Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial.
Sehouli J; Oskay-Ozcelik G; Kühne J; Stengel D; Hindenburg HJ; Klare P; Heinrich G; Schmalfeldt B; Mertens H; Camara O; Lichtenegger W;
Ann Oncol; 2006 Jun; 17(6):957-61. PubMed ID: 16600975
[TBL] [Abstract][Full Text] [Related]
40. Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer.
Bun S; Yunokawa M; Tamaki Y; Shimomura A; Shimoi T; Kodaira M; Shimizu C; Yonemori K; Fujiwara Y; Makino Y; Terakado H; Tamura K
Support Care Cancer; 2018 Jul; 26(7):2161-2166. PubMed ID: 29372396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
